drugset / Trial / NCT01839019

Safety and Tolerability Study With Single Ascending Doses of ODM-102

NCT01839019 ↗

Phase 1 Completed 22 enrolled Orion Corporation, Orion Pharma
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate the safety and tolerability of escalating single doses of ODM-102 in healthy volunteers

Timeline

Start
2013-04
Primary completion
2013-06
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject ODM-102 Unknown — —

Indications

No indication recorded.